{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:13:37Z","timestamp":1790313217751,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006927"],"award-info":[{"award-number":["P30 CA006927"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA176289"],"award-info":[{"award-number":["CA176289"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008321","name":"Pennsylvania State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005300","name":"American Chemical Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clcc.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T13:26:32Z","timestamp":1597843592000},"page":"e43-e52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Arthur","family":"Winer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal S.","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Astaturov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-2013","authenticated-orcid":false,"given":"Jean-Nicolas","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold A.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sivik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Korzekwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry S.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-2418","authenticated-orcid":false,"given":"Eric A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.08.003_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2020.08.003_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamasurg.2014.1756","article-title":"Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010","volume":"150","author":"Bailey","year":"2015","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clcc.2020.08.003_bib4","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clcc.2020.08.003_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib6","first-page":"1296","article-title":"Systemic treatment of colorectal cancer","volume":"134","author":"Mayer","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clcc.2020.08.003_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2020.08.003_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.08.003_bib9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ctrv.2014.10.004","article-title":"P53 as a target for the treatment of cancer","volume":"40","author":"Duffy","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2020.08.003_bib10","first-page":"1","article-title":"CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity","volume":"3","author":"Tanner","year":"2004","journal-title":"J\u00a0Negat Results Biomed"},{"key":"10.1016\/j.clcc.2020.08.003_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0049-0172(89)90050-4","article-title":"The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination","volume":"18","author":"Wallace","year":"1989","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clcc.2020.08.003_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4161\/cbt.4.8.2134","article-title":"Acridine derivatives activate p53 and induce tumor cell death through Bax","volume":"4","author":"Wang","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.08.003_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/cbt.12.3.17033","article-title":"Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents","volume":"12","author":"Wang","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.08.003_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/cbt.12.3.17034","article-title":"Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer","volume":"12","author":"Gallant","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.08.003_bib15","article-title":"Repurposing quinacrine for treatment-refractory cancer","author":"Oien","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clcc.2020.08.003_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fonc.2020.01118","article-title":"Repositioning quinacrine toward treatment of ovarian cancer by rational combination with TRAIL","volume":"10","author":"Liang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib17","doi-asserted-by":"crossref","first-page":"118995","DOI":"10.1016\/j.ijpharm.2019.118995","article-title":"Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: repurposing quinacrine for lung cancer therapeutics","volume":"577","author":"Vaidya","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clcc.2020.08.003_bib18","series-title":"Xeloda (capecitabine) [FDA package insert]","year":"2016"},{"key":"10.1016\/j.clcc.2020.08.003_bib19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/onc.2008.460","article-title":"9-Aminoacridine\u2013based anticancer drugs target the PI3K\/AKT\/mTOR, NF-\u03baB and p53 pathways","volume":"28","author":"Guo","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.clcc.2020.08.003_bib20","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12156-011-0074-3","article-title":"Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?","volume":"5","author":"Chintala","year":"2011","journal-title":"Oncol Rev"},{"key":"10.1016\/j.clcc.2020.08.003_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-3565(25)08921-9","article-title":"The pharmacological basis for the rational use of atabrine in the treatment of malaria","volume":"71","author":"Shannon","year":"1944","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clcc.2020.08.003_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clcc.2020.08.003_bib24","first-page":"1169","article-title":"WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis","volume":"54","author":"El-Deiry","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2020.08.003_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-4-53","article-title":"Pharmacokinetics of quinacrine in the treatment of prion disease","volume":"4","author":"Yung","year":"2004","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clcc.2020.08.003_bib26","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Fluorouracil plus leucovorin in patients with metastatic colorectal cancer\u00a0: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3904\/kjim.2015.049","article-title":"Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients","volume":"32","author":"Jung","year":"2017","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clcc.2020.08.003_bib28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12032-014-0870-2","article-title":"Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer","volume":"31","author":"Miger","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding\u2014a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.clcc.2020.08.003_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2133.1979.tb05599.x","article-title":"Mepacrine pigmentation in systemic lupus erythematosus. New data from an ultrastructural, biochemical and analytical electron microscopic investigation","volume":"101","author":"Leigh","year":"1979","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clcc.2020.08.003_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00432-010-0954-0","article-title":"Capecitabine-based chemotherapy for metastatic colorectal cancer","volume":"137","author":"Ling","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib32","first-page":"941","article-title":"Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients","volume":"4","author":"Roos Reigner","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2020.08.003_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s002800051118","article-title":"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients","volume":"44","author":"Cassidy","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2020.08.003_bib34","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/bjc.2013.517","article-title":"Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)","volume":"109","author":"Louie","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.08.003_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01849629","article-title":"100,000 quinacrine sterilizations","volume":"12","author":"Kessel","year":"1996","journal-title":"Adv Contracep"},{"key":"10.1016\/j.clcc.2020.08.003_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.2042-7158.1989.tb06421.x","article-title":"Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man","volume":"41","author":"Bjorkman","year":"1989","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.clcc.2020.08.003_bib37","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-15-2792","article-title":"Sorafenib and quinacrine target anti-apoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC)","volume":"22","author":"Abdulghani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2020.08.003_bib38","first-page":"751","article-title":"Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States","volume":"17","author":"Cho","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.08.003_bib39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-016-3197-1","article-title":"Research progress of hydroxychloroquine and autophagy inhibitors on cancer","volume":"79","author":"Shi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15 suppl","key":"10.1016\/j.clcc.2020.08.003_bib40","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2017.35.15_suppl.3545","article-title":"Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer","volume":"35","author":"O\u2019Hara","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00432-014-1628-0","article-title":"Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells","volume":"140","author":"Kaneko","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4251\/wjgo.v6.i3.74","article-title":"Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation","volume":"6","author":"Schonewolf","year":"2014","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","article-title":"Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial","volume":"5","author":"Karasic","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2020.08.003_bib44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archderm.1980.01640290097026","article-title":"Antimalarial agents chloroquine, hydroxychloroquine, and quinacrine","volume":"116","author":"Tanenbaum","year":"1980","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:33Z","timestamp":1761520053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820301079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1533002820301079"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.08.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}